[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655188":3},{"organization":4,"outcomesModule":7,"designInfo":47,"detailedDescription":14,"studyPopulation":14,"armGroups":53,"interventions":59,"overallOfficials":64,"centralContacts":69,"locations":14,"responsibleParty":75,"collaborators":14,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":14,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":14,"enrollmentInfo":86,"targetDuration":14,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":14,"overallStatus":95,"whyStopped":14,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":14},{"fullName":5,"class":6},"InventisBio Co., Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":44},[9,12,16],{"measure":10,"description":10,"timeFrame":11},"Number of subjects participants with adverse events","From enrollment to 30 days after last dose",{"measure":13,"description":14,"timeFrame":15},"Subject incidence of Dose-limiting toxicities (DLT)",null,"From enrollment to Cycle 1 Day 21",{"measure":17,"description":14,"timeFrame":18},"Objective response rate (ORR)","From enrollment to the end of treatment, about 1 year",[20,22,24,26,29,32,34,36,38,40,42],{"measure":21,"description":14,"timeFrame":18},"Disease control rate (DCR)-assessed by IRC and investigators",{"measure":23,"description":14,"timeFrame":18},"Progression free survival (PFS)",{"measure":25,"description":14,"timeFrame":18},"Duration of Response (DOR)",{"measure":27,"description":14,"timeFrame":28},"Change from baseline in QT\u002FQTc interval","On Cycle 0 Day 1 and Cycle 2 Day 1 (Cycle 0 is 7 days and the rest cycle is 21 days)",{"measure":30,"description":14,"timeFrame":31},"Primary PK parameters: area under the concentration-time curve from the time of dosing to time t (AUC0-t)","From Cycle 0 Day 1 to Cycle 0 Day 7 and on Cycle 2 Day 1 (Cycle 0 is 7 days and the rest cycle is 21 days)",{"measure":33,"description":14,"timeFrame":31},"Primary PK parameters: area under the concentration-time curve from time 0 to infinity (AUC0-∞)",{"measure":35,"description":14,"timeFrame":31},"Primary PK parameters: Mean residence time (MRT)",{"measure":37,"description":14,"timeFrame":31},"Primary PK parameters: maximum concentration (Cmax)",{"measure":39,"description":14,"timeFrame":31},"Primary PK parameters: Time to maximum concentration (Tmax)",{"measure":41,"description":14,"timeFrame":31},"Primary PK parameters: t1\u002F2",{"measure":43,"description":14,"timeFrame":31},"Primary PK parameters: Apparent Volume of Distribution (Vz\u002FF)",[45],{"measure":46,"description":14,"timeFrame":18},"Change from baseline in concentration and\u002For mutations in ctDNA",{"allocation":48,"interventionModel":49,"interventionModelDescription":14,"primaryPurpose":50,"observationalModel":14,"timePerspective":14,"maskingInfo":51},"NA","SINGLE_GROUP","TREATMENT",{"masking":52,"maskingDescription":14,"whoMasked":14},"NONE",[54],{"label":55,"type":56,"description":14,"interventionNames":57},"YF087","EXPERIMENTAL",[58],"Drug: YF087",[60],{"type":61,"name":55,"description":62,"armGroupLabels":63,"otherNames":14},"DRUG","Dosage form: Tablet • Administration route: Oral, once a day",[55],[65],{"name":66,"affiliation":67,"role":68},"Ruihua Xu, MD","Sun Yat-sen University Cancer Center (SYSUCC)","PRINCIPAL_INVESTIGATOR",[70],{"name":71,"role":72,"phone":73,"phoneExt":14,"email":74},"Yuting Li","CONTACT","8615821378026","yuting.li@inventisbio.com",{"type":76,"investigatorFullName":14,"investigatorTitle":14,"investigatorAffiliation":14,"oldNameTitle":14,"oldOrganization":14},"SPONSOR","100655188","phase-1-a-study-to-evaluate-yf087-in-subjects-with-msi-h-or-dmmr-advanced-solid-tumors-100655188",false,"NCT07809607","A Study to Evaluate YF087 in Subjects With MSI-H or dMMR Advanced Solid Tumors","An Open-Label, Multicenter, Phase I Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YF087 in Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Advanced Solid Tumors","Inclusion Criteria:\n\n* Subjects with locally advanced (unresectable) or metastatic solid tumors;\n* dMMR\u002FMSI-H status demonstrated in tumor tissue, blood, or other samples containing cancer cells or DNA;\n* Subjects must have experienced disease progression after the most recent therapy for advanced disease (prior therapy must include at least one PD-1\u002FPD-L1 inhibitor treatment).\n* Presence of at least 1 measurable lesion that can be measured by CT or MRI based on RECIST V1.1 criteria;\n* ECOG≤1\n\nExclusion Criteria:\n\n* Prior treatment with a WRN inhibitor such as HRO760, RO7589831, GSK4418959 and NDI-219216;\n* Prior to the first dose of study intervention, receipt of any anticancer treatment (including chemotherapy, targeted therapy, immunotherapy, etc.) or any other investigational medicinal product within 14 days or 3 half-lives (whichever is shorter);\n* Subjects with unstable or symptomatic or progressive central nervous system (CNS) metastases and\u002For leptomeningeal carcinomatosis and\u002For brainstem metastases and\u002For spinal cord compression;\n* Subjects with clinically significant cardiovascular and cerebrovascular disease\n* Subjects with concomitant medical conditions that the investigator believes may increase the risk of toxicity, such as serious cardiovascular, respiratory or neurological diseases;\n* Use of, or planned use of, any of the following medications that has not been discontinued for at least 14 days or 5 half-lives (whichever is shorter) before the first study drug administration:\n\n  1. Strong CYP3A4 inducers or inhibitors;\n  2. Drugs known to prolong the QT interval.\n* Pregnant or lactating females;","ALL","18 Years",{"count":87,"type":88},70,"ESTIMATED","INTERVENTIONAL",[91],"PHASE1","This is an open-label, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of YF087 in subjects with Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) advanced solid tumors.",[94],"Advanced Solid Tumor Cancer","NOT_YET_RECRUITING","2026-09-02",{"date":98,"type":99},"2026-09-09","ACTUAL",{"date":101,"type":88},"2026-09-18",{"date":103,"type":88},"2028-09-30",{"name":5,"class":6}]